藥明生物(02269.HK):建議於公開市場以不超6億美元總價格購回股份
格隆匯12月6日丨藥明生物(02269.HK)發佈公吿,根據購回授權,公司獲准於聯交所購回最多約4.25億股股份,佔於股東周年大會當日已發行股份總數的10%。董事會宣佈,2023年12月5日,其已議決動用購回授權,以不時在公開市場上以不超過6億美元總價格購回股份。
公司相信,股份目前的交易價格並未反映其內在價值或公司的實際業務前景,而建議股份購回也反映公司對其自身業務發展前景充滿信心。公司亦認為,公司目前的財務資源將使其能夠實施建議股份購回,同時維持穩健的財務狀況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.